Drug Profile
NCB 0846
Alternative Names: NCB-0846Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Carna Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Germinal centre kinase inhibitors; Transforming growth factor beta1 inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Japan
- 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 08 Jul 2016 Preclinical trials in Cancer in Japan (unspecified route)